Skip to main content
Terug
MLYS logo

Mineralys Therapeutics, Inc.

Datakwaliteit: 100%
Oversold
MLYS
NASDAQ Healthcare Biotechnology
€ 22,88
▼ € 0,77 (-3,26%)
Marktkapitalisatie: 1,52B
Dagbereik
€ 22,42 € 23,87
52-Weeksbereik
€ 10,44 € 47,65
Volume
784.570
50D / 200D Gem.
€ 29,55 / € 29,16
Vorige Slotkoers
€ 23,65

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -9,8 0,3
P/B 2,4 2,9
ROE % -36,9 3,7
Net Margin % 3,8
Rev Growth 5Y % 10,0
D/E 0,0 0,2

Koersdoel Analisten

Hold
€ 46,00 +101.0%
Low: € 30,00 High: € 56,00
Forward WPA
-€ 2,19
Omzet Sch.
560000

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 5,23
€ 2,67 – € 13,20
1,3 B 1
FY2029 € 2,48
€ 1,26 – € 6,25
750 M 1
FY2028 -€ 0,94
-€ 1,58 – -€ 0,28
250 M 5

Belangrijkste Punten

Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -142,43M
PEG of 0,42 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-36,91%
ROIC-19,79%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,00
Current Ratio43,76
Interest Coverage0,00

Waardering

P/E Ratio
-9,81
P/B Ratio2,35
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -154,65M
ROE -36,91% ROA -23,37%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -142,43M
ROIC -19,79% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 43,76
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -9,81 P/B Ratio 2,35
P/S Ratio N/A PEG Ratio 0,42
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,52B Enterprise Value 1,34B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 0,0 0,0 0,0 0,0
Net Income -154,65M -177,81M -71,90M -29,80M -19,41M
EPS (Diluted) -2,29 -3,66 -1,99 -5,77 -3,89
Gross Profit -59.000,0 0,0 0,0 0,0 0,0
Operating Income -170,60M -192,40M -84,66M -31,48M -18,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 661,81M 205,90M 251,64M 114,44M 11,13M
Total Liabilities 15,11M 14,65M 10,48M 166,71M 34,05M
Shareholders' Equity 646,69M 191,26M 241,15M -52,27M -22,93M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 172,92M 114,09M 49,30M 87,70M 10,61M
Current Assets 661,39M 205,35M 249,10M 112,81M 11,12M
Current Liabilities 15,11M 14,65M 10,48M 8,07M 5,05M